1-3 of 3
Jiřina Procházková
Close
Sort by
Journal Articles

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Daniela Žácková, Edgar Faber, Lukáš Stejskal, Michal Karas, Petra Bělohlávková, Hana Klamová, Olga Černá, Eduard Cmunt, Petra Čičátková, Lukáš Semerád, Tomáš Horňák, Anežka Kvetková, Jiřina Procházková, Jitka Rychlíčková, Radka Štěpánová, Adam Svobodník, Kateřina Machová Poláková, Ivana Ježíšková, Tomáš Jurček, Marek Borský, Ondřej Wiewiorka, Regina Demlová, Jiří Mayer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3606.
https://doi.org/10.1182/blood-2021-146221
Published: 2021
Journal Articles

Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience

Ekaterina Bulycheva, MD, Jiri Mayer, Prof., MD, William Hermann Krüger, MD PhD, Peter Dreger, MD, Anna Mies, Zuzana Sustkova, MD, Zdenek Racil, MD, Jirina Prochazkova, MD, Eva Walter, MD, Carsten Hirt, Mark Ringhoffer, MD, Wolfgang E Berdel, MD, Hubert Serve, MD, Christoph Rollig, Katja Sockel, MD, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Christian Thiede, MD PhD, Uwe Platzbecker, MD
Journal: Blood
Blood (2015) 126 (23): 3817.
https://doi.org/10.1182/blood.V126.23.3817.3817
Published: 2015
Journal Articles

Clinical Manifestation of 1000 Leukemias.

Zdenek Racil, MD, PhD, Jiri Mayer, Prof., MD, PhD, Martin Brejcha, MD, Petr Cetkovsky, MD., PhD., Jirina Prochazkova, Rene Zounar
Journal: Blood
Blood (2009) 114 (22): 4134.
https://doi.org/10.1182/blood.V114.22.4134.4134
Published: 2009